Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,394 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A New Self-Expandable Metallic Stent with Low Axial Force and a High Axial Force Zero-Border Shows a Very Low Perforation Rate in Malignant Colorectal Obstruction: A Japanese Multicenter Prospective Study.
Murakami T, Isayama H, Ikeda S, Hanabata N, Enomoto T, Kuwai T, Ushigome M, Ebi M, Ohtsuka H, Endo S, Saito S, Ohki T, Yamamoto R, Kayahara T, Matsumoto S, Sasaki Y, Saida Y. Murakami T, et al. Among authors: enomoto t. J Clin Med. 2024 Aug 28;13(17):5102. doi: 10.3390/jcm13175102. J Clin Med. 2024. PMID: 39274314 Free PMC article.
Prospective Multicenter Study to Clarify the Frequency of Peristomal Skin Disorders and Appropriate Evaluation Time in Patients with Malignant Rectal Tumors.
Shiraishi T, Nishizawa Y, Nakajima M, Kado R, Ogawa H, Naomi S, Owada Y, Enomoto T, Yazawa S, Hamahata Y, Isogami Y, Kitagawa K, Sakamoto M, Enomoto H, Egawa A, Kitaguchi D, Hasegawa H, Ikeda K, Tsukada Y, Ito M. Shiraishi T, et al. Among authors: enomoto t. Ann Surg. 2024 Sep 6. doi: 10.1097/SLA.0000000000006522. Online ahead of print. Ann Surg. 2024. PMID: 39239714
Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan.
Nakane K, Taniguchi K, Nezasa M, Enomoto T, Yamada T, Tomioka-Inagawa R, Niwa K, Tomioka M, Ishida T, Nagai S, Yokoi S, Taniguchi T, Kawase M, Kawase K, Iinuma K, Tobisawa Y, Koie T. Nakane K, et al. Among authors: enomoto t. Cancers (Basel). 2024 Jul 25;16(15):2648. doi: 10.3390/cancers16152648. Cancers (Basel). 2024. PMID: 39123376 Free PMC article.
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.
Colombo N, Biagioli E, Harano K, Galli F, Hudson E, Antill Y, Choi CH, Rabaglio M, Marmé F, Marth C, Parma G, Fariñas-Madrid L, Nishio S, Allan K, Lee YC, Piovano E, Pardo B, Nakagawa S, McQueen J, Zamagni C, Manso L, Takehara K, Tasca G, Ferrero A, Tognon G, Lissoni AA, Petrella M, Laudani ME, Rulli E, Uggeri S, Barretina Ginesta MP; AtTEnd study group. Colombo N, et al. Lancet Oncol. 2024 Sep;25(9):1135-1146. doi: 10.1016/S1470-2045(24)00334-6. Epub 2024 Aug 2. Lancet Oncol. 2024. PMID: 39102832 Clinical Trial.
1,394 results